Atlas Trials

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Clinical trial NCT01934140 · COMPLETED

Trial details

NCT number
NCT01934140
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Infections, Meningococcal
Start date
2014-04-01
Primary completion
2018-02-01
Enrollment
311

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.